The 3rd EU HCV Policy Virtual Summit on 24 March 2021 explores barriers to elimination

Despite the progress that’s been made in recent years, viral hepatitis remains a serious public health threat worldwide. In the World Health Organization (WHO) European region an estimated 15 million people are living with chronic hepatitis B, and 14 million people are living with hepatitis C. The public health threat of hepatitis has been exacerbated by the COVID-19 pandemic with many countries reporting disruption to hepatitis services due to strained healthcare systems and shifting priorities, putting the 2030 elimination goals in jeopardy.

The third EU HCV Policy Summit will bring together policy-makers, experts, members of parliament, directors of national hepatitis C elimination plans, mayors, patient associations, clinicians and Members of the European Parliament to raise awareness on the state of play regarding the goal of hepatitis C by 2030 and showcase best practices as well as indicate what policy actions are needed to get more countries on track to achieve hepatitis C elimination by 2030. The summit is taking place on Wednesday 24 March 2021 from 14:00 to 18:15 CET.

Speakers include:
Mr Alexis Goosdeel, Director, European Monitoring Centre for Drugs & Drug Addiction (EMCDDA)
Dr. Pilar Aparicio Azcárraga, MD, PhD, Director General of Public Health, Ministry of Health, Spain
Dr. Yuval Dadon, MD MBA, Ministry of Health, Israel
Dr Antons Mozalevskis, MD, Joint Tuberculosis, HIV and Viral Hepatitis Programme, Regional Office for Europe, World Health Organization, Copenhagen, Denmark
Dr. Ricardo Baptista Leite, MP, MD, Ph, National Parliament Portugal & UNITE – Global Parliamentarians Network
Dr. Homie Razavi, Center for Disease Analysis, Lafayette, CO USA

Chairs include:
Prof. Angelos Hatzakis MD, PhD, MSc, Medical School of National and Kapodistrian University of Athens, Greece
Prof. Nurdan Tözün MD, FRCP, Acibadem University School of Medicine, Istanbul, Turkey

For a full list of speakers and chairs please click here.

For draft programme please click here.

For free registration please click here.

Latest News

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close